Nexien BioPharma (NXEN) S-1/A 11 Jun 18 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Mar. 31, 2018
Document And Entity Information
Entity Registrant Name	Intiva BioPharma Inc.
Entity Central Index Key	1,625,288
Document Type	S-1/A
Document Period End Date	Mar. 31, 2018
Amendment Flag	true
Amendment Description	Amendment No. 1
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NTVA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current Assets
Cash	$ 733,399	$ 242,778
Due from related party	114,667	141,329
Total current assets	848,066	384,107
Deposit for acquisition of Kinder Holdings Corp.		86,670
License	337,915	302,915
Total Assets	1,185,981	773,692
Current Liabilities
Accounts payable and accrued expenses	53,138	210,405
Total current liabilities	53,138	210,405
Total liabilities	53,138	210,405
Commitments and contingencies (Notes 3, 4 and 8)
Stockholders' Equity
Preferred stock, $.0001 par value; 10,000,000 authorized; none issued
Common stock-$.0001 par value; 200,000,000 shares authorized; 43,756,096 shares issued and outstanding -March 31, 2018; and 32,615,112 shares- June 30, 2017	4,376	3,262
Additional paid in capital	2,616,966	1,235,457
Common stock subject to forfeiture	(275,001)
Common stock subscription receivable		(484,000)
Accumulated deficit	(1,213,498)	(191,432)
Total Stockholders' Equity	1,132,843	563,287
Total Liabilities and Stockholders' Equity	$ 1,185,981	$ 773,692

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Jun. 30, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Common stock, par value	$ .0001	$ .0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	43,756,096	32,615,112
Common stock, shares outstanding	43,756,096	32,615,112

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended			9 Months Ended
	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenue
Operating expenses
Legal fees		$ 170,661
Professional fees	93,782			279,160
Research and development	875	12,261	61,196	90,720	61,196
Stock based compensation	45,833			434,516
General and administrative	127,238	8,510	6,025	217,670	6,025
Total operating expenses	267,728	191,432	67,221	1,022,066	67,221
Net loss	$ (267,728)	$ (191,432)	$ (67,221)	$ (1,022,066)	$ (67,221)
Loss per share - basic and diluted	$ (0.01)	$ (0.01)	$ (0.003)	$ (0.02)	$ (0.003)
Weighted average shares outstanding - basic and diluted	44,578,382	24,421,427	24,000,000	42,298,532	24,000,000

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Subscription Receivable [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Mar. 26, 2017
Beginning Balance, shares at Mar. 26, 2017
Stock issued for costs and expenses at $0.0084 per share to founders	$ 2,400	198,828			201,228
Stock issued for costs and expenses at $0.0084 per share to founders, shares	24,000,000
Stock issued for cash at $0.1125	$ 83	93,417			93,500
Stock issued for cash at $0.1125, shares	831,112
Share issuance costs- $0.1125 PPM		(6,545)			(6,545)
Stock issued for cash at $.125	$ 779	972,221	(484,000)		489,000
Stock issued for cash at $.125, shares	7,784,000
Share issuance costs- $10.00 per unit PPM		(22,464)			(22,464)
Net loss				(191,432)	(191,432)
Ending Balance at Jun. 30, 2017	$ 3,262	$ 1,235,457	$ (484,000)	$ (191,432)	563,287
Ending Balance, shares at Jun. 30, 2017	32,615,112
Net loss					(1,022,066)
Ending Balance at Mar. 31, 2018					$ 1,132,843

Consolidated Statement of Stoc6

Consolidated Statement of Stockholders' Equity (Parenthetical)	Jun. 30, 2017$ / shares
Stock price per share	$ 0.1125
Stock price per unit	0.1125
Common Stock [Member]
Stock price per share	0.125
Stock price per unit	10
Founders [Member]
Stock price per share	$ 0.0084

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net loss	$ (191,432)	$ (1,022,066)	$ (67,221)
Adjustments to reconcile net loss to net cash used in operating activities
Stock based compensation		434,516
Changes is assets and liabilities
Decrease in due from related party	(138,330)	26,662
Increase in advance from officers			52,000
Increase (decrease) in accounts payable and accrued expenses	148,255	(134,803)	67,196
Cash used in operating activities	(181,507)	(695,691)	51,975
Cash flows from investing activities
Cash paid for license	(65,000)	(35,000)
Cash paid for acquisition deposit	(86,670)	(12,900)	(50,000)
Cash used in investing activities	(151,670)	(47,900)	(50,000)
Cash flows from financing activities
Cash proceeds from issuance of common stock	582,500	1,261,592
Payment of offering costs	(6,545)	(27,380)
Cash provided by financing activities	575,955	1,234,212
Net increase in cash and cash equivalents	242,778	490,621	1,975
Cash and cash equivalents, beginning of period		242,778
Cash and cash equivalents, end of period	242,778	733,399	1,975
Supplemental disclosure of non-cash investing and financing activities
Issuance of common stock to related party for costs and expenses	201,228
Unpaid license costs	65,000
Unpaid offering costs	$ 22,464
Shares issued for Kinder Exchange		$ 99,570

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Note 1 – Nature of Business and Basis of Presentation The Company was incorporated on November 10, 1952 in Michigan as Gantos, Inc. On July 21, 2008, the Company completed its change in domicile to Delaware and subsequently changed its name to Kinder Holding Corp. (the “Company”). As of October 13, 2017, the Company completed a reverse acquisition of Intiva BioPharma Inc., a Colorado corporation (“BioPharma”) through an exchange of shares (the “Share Exchange Transaction”). In connection with the Share Exchange Transaction, the Company changed its name to Intiva BioPharma Inc. on November 8, 2017. As further described in Note 3, BioPharma became a wholly-owned subsidiary of the Company. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). The operations of BioPharma were the only continuing operations of the Company. The accompanying financial statements as of June 30, 2007 and for the period then ended present the historical financial information of BioPharma. BioPharma was incorporated under the laws of the State of Colorado on March 27, 2017 to pursue pre-clinical and drug development activities, in accordance with U.S. Food and Drug Administration (“FDA”) protocols, for certain pharmaceutical formulations that include cannabinoids. It is pursuing the formulation and development of cannabinoid-based drugs for medical conditions and disorders, and owns a license covering certain intellectual property, including certain patent applications, and has filed six of its own provisional patent applications for other drugs that include cannabinoids and other substances, including terpenes, that are intended to be developed with the objective of treating certain medical conditions and disorders. It was formed as a corporate subsidiary of the Colorado corporation Intiva USA Inc. (“Intiva USA”), which is a subsidiary of the Ontario, Canada corporation, Kanativa Inc. (formerly Intiva Inc.). Principles of Consolidation The accompanying consolidated financial statements include BioPharma and its wholly owned subsidiaries: Intiva Kotzker Pharmaceuticals Inc. (“Intiva Kotzker”) and Intiva Sharir Inc. (collectively “the Company”), and were prepared from the accounts of the Company in accordance with accounting principles generally accepted in the United States of America (US GAAP). All significant intercompany transactions and balances have been eliminated on consolidation. Basis of Presentation/Going Concern Uncertainty All share and per share amounts have been adjusted in the footnotes and accompanying financial statements to give effect to the Share Exchange Transaction. (See Note 3). The accompanying financial statements have been prepared in conformity with US GAAP, which contemplates continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception of $191,432. The development of pharmaceuticals with the objective of obtaining approval by the FDA and other international regulatory authorities is not a short-term endeavor for any specific drug candidate. It also requires extremely significant amounts of capital funding for clinical trials and other matters. At June 30, 2017, the Company had working capital of $173,702, and received an additional $906,500 subsequent to June 30, 2017 as proceeds from the Company’s private placement of common stock and warrants (see Note 5). The Company will require significant additional capital to fund the implementation and execution of its business plan. This capital, which likely will be millions of dollars for a single drug candidate, will be required for research, regulatory applications, and clinical trials. At the present time, the Company does not have any commitments or known sources for this level of funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.	Note 1 – Nature of Business and Basis of Presentation The Company was incorporated on November 10, 1952 in Michigan as Gantos, Inc. On July 21, 2008, the Company completed its change in domicile to Delaware and subsequently changed its name to Kinder Holding Corp. (the “Company”). As of October 13, 2017, the Company completed a reverse acquisition of Intiva BioPharma Inc., a Colorado corporation (“BioPharma”) through an exchange of shares (the “Share Exchange Transaction”). In connection with the Share Exchange Transaction, the Company changed its name to Intiva BioPharma Inc. on November 8, 2017. As further described in Note 3, BioPharma became a wholly-owned subsidiary of the Company. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). The operations of BioPharma were the only continuing operations of the Company. The accompanying financial statements as of March 31, 2018 and for the three and nine-month periods ended March 31, 2017 and 2018 present the historical financial information of BioPharma. BioPharma was incorporated under the laws of the State of Colorado on March 27, 2017 to pursue pre-clinical and drug development activities, in accordance with U.S. Food and Drug Administration (“FDA”) protocols, for certain pharmaceutical formulations that include cannabinoids. It is pursuing the formulation and development of cannabinoid-based drugs for medical conditions and disorders, and owns a license covering certain intellectual property, including certain patent applications, and has filed six of its own provisional patent applications for other drugs that include cannabinoids and other substances, including terpenes, that are intended to be developed with the objective of treating certain medical conditions and disorders. It was formed as a corporate subsidiary of the Colorado corporation Intiva USA Inc. (“Intiva USA”), which is a subsidiary of the Ontario, Canada corporation, INTIVA Inc., now known as Kanativa Inc. All share and per share amounts have been adjusted in the footnotes and accompanying financial statements to give effect to the Share Exchange Transaction. As disclosed in Note 3, for financial reporting purposes, the Share Exchange Transaction is accounted for as an additional capitalization of BioPharma with BioPharma as the accounting acquirer (reverse acquirer). The operations of BioPharma are the continuing operations of the Company. Principles of Consolidation The accompanying consolidated financial statements include BioPharma and its wholly owned subsidiaries: Intiva Kotzker Pharmaceuticals Inc. (“Intiva Kotzker”) and Intiva Sharir Inc. (collectively “the Company”), and were prepared from the accounts of the Company in accordance with accounting principles generally accepted in the United States of America (US GAAP). All significant intercompany transactions and balances have been eliminated on consolidation. Basis of Presentation The Financial Statements presented herein have been prepared in accordance with the accounting policies described in the June 30, 2017 audited financial statements and should be read in conjunction with the notes to financial statements which appear as part of those financial statements. The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets, income taxes, insurance obligations and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other resources. Actual results may differ from these estimates under different assumptions or conditions. In the opinion of Management, the information furnished in these interim financial statements reflects all adjustments necessary for a fair statement of the financial position and results of operations and cash flows as of March 31, 2018 and for the three and nine-month periods ended March 31, 2017 and 2018. All such adjustments are of a normal recurring nature.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at June 30, 2017. Valuation of Long-Lived Assets The Company reviews the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations. Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At June 30, 2017, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The assets or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the period ended June 30, 2017, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As of June 30, 2017, no assets or liabilities were required to be measured at fair value on a recurring basis. Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Certain estimates and judgments must be made in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of the Company’s net deferred tax assets is dependent upon generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. Management has determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all the Company’s net deferred tax asset. Management will continue to evaluate the realization of the deferred tax asset and its related valuation allowance. If assessment of the deferred tax assets or the corresponding valuation allowance were to change, the Company would record the related adjustment to income during the period in which the determination is made. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. Liabilities for anticipated tax audit issues in the U.S. are recognized based on the estimate of whether, and to the extent to which, additional taxes will be due. If it is ultimately determined that payment of these amounts is unnecessary, the liability will be reversed and a tax benefit will be recognized during the period in which it is determined that the liability is no longer necessary. The Company will record an additional charge to the provision for taxes in the period in which it is determined that the recorded tax liability is less than the Company expects the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Research and Development Expenses Research and development expenses are charged to operations as incurred. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk. Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other (Topic 350). ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2018. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard will be effective for the Company in the first quarter of 2018. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 amended guidance regarding accounting for Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. When effective, this standard will replace most existing revenue recognition guidance in GAAP. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not comprehensively addressed in GAAP. This guidance is required to be adopted by us in the first quarter of fiscal 2019 by either recasting all years presented in our financial statements or by recording the impact of adoption as an adjustment to retained earnings at the beginning of the year of adoption. We are currently evaluating the impact this guidance will have on our consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control. The amendments in this Update improve GAAP involving situations consisting of common control, wherein a single decision maker focuses on the economics to which it is exposed when determining whether it is the primary beneficiary of a variable interest entity (“VIE”) before potentially evaluating which party is most closely associated with the VIE. ASU 2016-17 is effective for public entities for fiscal periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which reduces the complexity in the accounting standards by allowing the recognition of current and deferred income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities as of the beginning of an annual reporting period for which financial statements (interim or annual) have not been issued or made available for issuance. That is, earlier adoption should be in the first interim period if an entity issues interim financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	9 Months Ended
	Mar. 31, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently Issued Accounting Pronouncements	Note 2 – Recently Issued Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other (Topic 350). ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2018. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard will be effective for the Company in the first quarter of 2018. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Share Exchange Agreement and Ac

Share Exchange Agreement and Acquisition Deposit	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Business Combinations [Abstract]
Share Exchange Agreement and Acquisition Deposit	Note 3 – Share Exchange Agreement and Acquisition Deposit On August 8, 2017, the Company entered into a Share Exchange Agreement, as amended and restated on October 13, 2017, (the “Agreement”), with BioPharma. Pursuant to the terms of the Agreement, the Company agreed to issue to the shareholders of BioPharma 42,642,712 post-reverse stock-split shares of the Company’s common stock, par value $0.0001 (“Common Stock”), in exchange for all of the issued and outstanding shares of BioPharma capital stock, thereby making BioPharma a wholly-owned subsidiary of the Company. As part of the Closing of the Agreement, the 20,000,000 pre-reverse split shares of the Company’s Common Stock previously purchased by Intiva USA, effective on June 26, 2017 in a change in control transaction from the Company’s control shareholders, shall be canceled. In June 2017, pursuant to a Debt Purchase Agreement, BioPharma paid $86,670 to a director of the Company to satisfy the Company’s debt obligation to the director and for BioPharma to purchase the debt obligation. The amount paid is classified as a non-current asset on the accompanying June 30, 2017 consolidated balance sheet. At June 30, 2017, BioPharma was owed $141,329 from Intiva USA for advances made by BioPharma on behalf of Intiva USA in conjunction with Intiva USA acquiring the controlling shareholding position in the Company. This amount is classified as a current asset on the accompanying June 30, 2017 consolidated balance sheet. Subsequent to June 30, 2017, $25,000 of the advance was repaid by Intiva USA.	Note 3 –Share Exchange Agreement and Acquisition Deposit On August 8, 2017, the Company entered into a Share Exchange Agreement, as amended and restated on October 13, 2017, (the “Agreement”), with BioPharma. Pursuant to the terms of the Agreement, the Company agreed to issue to the shareholders of BioPharma 42,642,712 post-reverse stock-split shares of the Company’s common stock, par value $0.0001 (“Common Stock”), in exchange for all of the issued and outstanding shares of BioPharma capital stock, thereby making BioPharma a wholly-owned subsidiary of the Company. As part of the Closing of the Agreement, the 20,000,000 pre-reverse split shares of the Company’s Common Stock previously purchased by Intiva USA, effective on June 26, 2017 in a change in control transaction from the Company’s control shareholders, shall be canceled. Subsequent to the Closing, the Company agreed to undertake to implement certain corporate actions, including filing with the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation to: ● Increase the number of shares of authorized Common Stock to 200,000,000 shares from 100,000,000 shares. ● Change the name of the company from Kinder Holding Corp. to Intiva BioPharma Inc. ● Implement a one for six (1:6) reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share. On October 13, 2017, the Closing of the Agreement became effective, and as a result of the Share Exchange, BioPharma became a wholly-owned subsidiary of the Company and the results of business will be consolidated on the Company’s consolidated financial statements. For financial reporting purposes, the transaction is to be accounted for as an additional capitalization of BioPharma with BioPharma as the accounting acquirer (reverse acquirer). The operations of BioPharma will be the continuing operations of the Company. In June 2017, pursuant to a Debt Purchase Agreement, BioPharma paid $86,670 to a former director of the Company to satisfy the debt obligation of the Company to the director and for BioPharma to purchase the debt obligation. The amount paid and additional costs paid by BioPharma on behalf of the Company subsequent to June 30, 2017 of $12,900 aggregated $99,570, was classified as a non-current asset on the accompanying June 30, 2017 consolidated balance sheet.

License Agreement

License Agreement	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
License Agreement
License Agreement	Note 4 – License Agreement In March 2017, Intiva Kotzker licensed certain intellectual property from Kotzker Consulting LLC (“Kotzker Consulting”), an unrelated entity. The licensed intellectual property includes patent applications relating to the use of cannabinoid receptor modulators and terpenes in the acute treatment during exposure to organophosphorus nerve agents and/or organophosphorus insecticides. Under terms of the agreement, Intiva Kotzker shall use its commercially reasonable efforts to develop and commercialize the licensed products, and, in particular, will be responsible for the design, manufacturing, preclinical, clinical, and regulatory development activities of the licensed products and shall bear the costs of such activities. As consideration for entering into the agreement, Intiva Kotzker agreed to: (i) pay Kotzker Consulting $180,000, (ii) pay patent prosecution costs incurred as of the date of the agreement of $15,000 and (iii) issue to Kotzker Consulting 31,550 shares of Kanativa Inc.’s common stock valued at $78,875 ($2.50 per share based on a contemporaneous private placement to third parties of Kanativa Inc.’s common stock). The Company has capitalized legal fees of $29,040 incurred in conjunction with acquiring the license agreement. As of June 30, 2017, $65,000 was due under the license agreement, which amount was paid in August 2017. The license agreement terminates, on a country by country basis, upon the expiration of the licensed patent for the licensed intellectual property, or when a competitor generic product utilizing the licensed technology is marketed in the particular country. Intiva Kotzker shall be responsible for development milestone payments for (i) licensed products for use as a preventative and therapeutic neuroprotective against nerve agents and pesticides and (ii) licensed products for treatment of diseases. Milestone payments for each of the foregoing will each be due in two payments, the first payment no later than thirty (30) days from acceptance of submission of the regulatory filing of the first licensed product and the second payment no later than thirty (30) days from approval of the first licensed product. Royalties will be due beginning with first commercial sale of developed products. The Company has completed and submitted a Pre-Investigational New Drug meeting request and amendment thereto with the FDA, with the objective of scheduling a meeting with the FDA in Washington, D.C, to discuss its proposed formulations and project development program.	Note 4 – License Agreement In March 2017, Intiva Kotzker licensed certain intellectual property from Kotzker Consulting LLC (“Kotzker Consulting”), an unrelated entity. The licensed intellectual property includes patent applications relating to the use of cannabinoid receptor modulators and terpenes in the acute treatment during exposure to organophosphorus nerve agents and/or organophosphorus insecticides. Under terms of the agreement , Intiva Kotzker shall use its commercially reasonable efforts to develop and commercialize the licensed products, and, in particular, will be responsible for the design, manufacturing, preclinical, clinical, and regulatory development activities of the licensed products and shall bear the costs of such activities. As consideration for entering into the agreement, Intiva Kotzker agreed to: (i) pay Kotzker Consulting $180,000, (ii) pay patent prosecution costs incurred as of the date of the agreement of $15,000 and (iii) issue to Kotzker Consulting 31,550 shares of Intiva Inc.’s common stock valued at $78,875 ($2.50 per share based on recent private placement to third parties of Intiva Inc.’s common stock). The Company has capitalized legal fees of $29,040 incurred in conjunction with acquiring the license agreement, As of June 30, 2017, $65,000 was due under the license agreement, which amount was paid in August 2017. The total value ascribed to the License Agreement with Kotzker Consulting is $302,915. The license agreement terminates, on a country by country basis, upon the expiration of the licensed patent for the licensed intellectual property, or when a competitor generic product utilizing the licensed technology is marketed in the particular country. On February 28, 2018, the Company obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications. Upon execution of the agreement, $35,000 was paid to the licensor, and payments of $30,000 and $35,000 are required by August 31, 2018 and February 28, 2019, respectively. The Company is required to pay milestone payments upon obtaining regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products. The Company may grant sublicenses under the terms of the agreement.

Stockholders' Equity

Stockholders' Equity	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Equity [Abstract]
Stockholders' Equity	Note 5 – Stockholders’ Equity Common stock In March 2017, the Company issued 24,000,000 shares of its common stock to Intiva USA as consideration for costs and expenses paid by Intiva USA on behalf of BioPharma and Intiva Kotzker aggregating $201,228. In May 2017, a private placement of 831,112 shares of BioPharma’s Common Stock was completed at a price of $0.1125 per share, for total proceeds of $93,500, to three non-affiliates of BioPharma. One of the non-affiliate investors in the May 2017 private placement subsequently became a director and officer of BioPharma. Offering costs associated with the private placement of $6,545 were recorded against the gross proceeds received from the offering. In May 2017, BioPharma commenced a private placement of 1,116,400 units of Common Stock and Warrants at a price of $1.25 per unit. Each unit consisted of ten shares of Common Stock, one Class A Warrant to purchase one share of Common Stock at $0.25 per share, one Class B Warrant to purchase one share of Common Stock at $0.38 per share and one Class C Warrant to purchase one share of Common Stock at $0.50 per share. As of June 30, 2017, 778,400 units have been sold, for total gross proceeds of $973,000, including 387,200 units which were subscribed but for which funds had not been received. The 3,872,000 shares underlying the subscribed units in the amount of $484,000 are included as issued and outstanding shares at June 30, 2017, and the related $484,000 subscription receivable is recorded as a component of stockholders’ equity on the accompanying consolidated balance sheet. Subsequent to June 30, 2017, the Company received proceeds of $484,000 for the subscribed shares. Offering costs associated with the private placement of $22,464 were recorded against the gross proceeds received from the offering. The relative fair value of the warrants attached to the common stock issued was estimated at the date of grant using the Black-Sholes pricing model. The relative fair value attached to the common stock component is $794,372 and the relative fair value of the warrants is $178,628 as of the grant date. The following table summarizes information about warrants outstanding at June 30, 2017: Number Exercise Price Expires Class A 778,400 $ 0.25 Jan. 31, 2018 Class B 778,400 $ 0.38 May 7, 2018 Class C 778,400 $ 0.50 July 14, 2018	Note 5 –Stockholders’ Equity Common stock In May 2017, BioPharma commenced a private placement of 1,116,400 units of Common Stock and Warrants at a price of $1.25 per unit. Each unit consisted of ten shares of Common Stock, one Class A Warrant to purchase one share of Common Stock at $0.25 per share, one Class B Warrant to purchase one share of Common Stock at $0.38 per share and one Class C Warrant to purchase one share of Common Stock at $0.50 per share. As of June 30, 2017, 778,400 units had been sold, for total gross proceeds of $973,000, including 387,200 units which were subscribed but for which funds had not been received. The 3,872,000 shares underlying the subscribed units in the amount of $484,000 were included as issued and outstanding shares at June 30, 2017, and the related $484,000 subscription receivable was recorded as a component of stockholders’ equity on the June 30, 2017 consolidated balance sheet. Subsequent to June 30, 2017, the Company received proceeds of $484,000 for the subscribed shares. In July and August 2017, BioPharma sold an additional 338,000 units (3,380,000 shares) for gross proceeds of $422,500. On August 10, 2017, BioPharma adopted the “2017 Stock Incentive Plan” and granted an aggregate of 6,400,000 shares of BioPharma Common Stock to five officers and directors of the Company, valued at $800,000 ($0.125 per share). One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017. In March 2018, the Company cancelled 1,166,667 unvested shares previously issued to its former CEO. As of March 31, 2018, 2,200,008 of the shares issued (valued at $275,001) are subject to forfeiture until vesting occurs. On August 25, 2017, BioPharma entered into consulting agreements with two unrelated individuals for (i) developing and maintaining social media portals and (ii) identifying and developing potential strategic partners for the Company’s various drug development activities. The agreements are each for a three-month term, payable monthly in shares of the Company’s common stock, valued at $0.125 per share, of an aggregate 304,800 shares and 138,000 shares, respectively. As of March 31, 2018, an aggregate 442,800 shares of common stock, valued at $55,350, representing all amounts due pursuant to the consulting agreements, have been issued to the two individuals. On September 1, 2017, BioPharma commenced a private placement sale of its common stock at $0.25 per share. The Company sold 100,000 shares for gross proceeds of $25,000, before offering costs of $4,916. In January 2018, BioPharma commenced a unit private placement of Common Stock and Warrants at a price of $2.10 per unit. Each Unit consisted of two shares of Common Stock and one Warrant to purchase an additional share of common stock at a price of $2.90 per share for a term of six months commencing with the date of acceptance of the underlying subscription agreement. As of March 31, 2018, the Company received proceeds of $25,200 from the sale of 12,000 units. On March 31, 2018, the Company’s board of directors approved and recommended for adoption by the stockholders of the Company a 2018 Equity Incentive Plan and has reserved 8,000,000 shares of Common Stock for issuance under the terms of that Plan. No awards have been granted under this Plan as of the date of this report. Warrants The relative fair value of the warrants attached to the common stock issued in the May 2017 private placement of units was estimated at the date of grant using the Black-Sholes pricing model. The relative fair value attached to the common stock component is $1,139,573 and the relative fair value of the warrants is $255,927 as of the grant date. The following table summarizes information about warrants outstanding at March 31, 2018: Number Exercise Price Expires Class B 1,038,000 $ 0.38 June 7, 2018 Class C 1,046,400 $ 0.50 July 14, 2018 During the quarter ended March 31, 2018, warrants were exercised as follows: Number Exercise Price Gross Proceeds Class A 812,400 $ 0.25 $ 203,100 Class B 14,400 $ 0.38 $ 5,472 Class C 12,000 $ 0.50 $ 6,000 The relative fair value of the warrants attached to the common stock issued in the January 2018 private placement of units was estimated at the date of grant using the Black-Sholes pricing model. The relative fair value attached to the common stock component is $19,762 and the relative fair value of the warrants is $5,438 as of the grant date. As of March 31, 2018, there are 12,000 warrants exercisable at a price of $2.90 per share through July 15, 2018.

Related Party Transactions

Related Party Transactions	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions BioPharma was formed as a subsidiary of Intiva USA, which is a subsidiary of Kanativa Inc. (formerly Intiva Inc.). Intiva USA was issued 24,000,000 shares of BioPharma’s common stock as consideration for its contribution of 100% of the ownership of Intiva Kotzker, and costs and expenses incurred on behalf of BioPharma and Intiva Kotzker in the amount of $201,228. Included in the consideration for the issuance of the common stock is $172,915 of capitalized license agreement costs comprised of (i) the value of Kanativa Inc. common stock issued to Kotzker Consulting of $78,875 and (ii) payments to Kotzker Consulting and legal costs in the aggregate of $94,040 (See Note 4). At June 30, 2017, BioPharma was owed $141,329 from Intiva USA for advances made by BioPharma on behalf of Intiva USA in conjunction with the Share Exchange Agreement (See Note 3). Subsequent to June 30, 2017, $25,000 has been repaid by Intiva USA. The Company’s Chairman, former Chief Executive Officer and Chief Financial Officer are also officers and/or directors of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.	Note 6 –Related Party Transactions BioPharma was formed as a subsidiary of Intiva USA, which is a subsidiary of Kanativa Inc. (formerly INTIVA Inc.). At June 30, 2017, BioPharma was owed $141,329 from Intiva USA for advances made by BioPharma on behalf of Intiva USA in conjunction with the Share Exchange Agreement (See Note 3). During the nine months ended March 31, 2018, $26,662 was repaid by Intiva USA. The balance due from Intiva USA at March 31, 2018 of $114,667 is classified as a current asset on the accompanying March 31, 2018 consolidated balance sheet. In March 2018, the Company cancelled 1,166,667 unvested shares of common stock previously issued to its former CEO under the Company’s 2017 Stock Incentive Plan. The Company’s Chairman, and Chief Financial Officer are also officers and/or a director of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 – Income Taxes The Company has adopted ASC 740 which provides for the recognition of a deferred tax asset based upon the value the loss carry-forwards will have to reduce future income taxes and management’s estimate of the probability of the realization of these tax benefits. The Company has a current operating loss carry-forward of approximately $191,432 resulting in a deferred tax asset of $70,945. The Company has determined it is more likely than not that the related deferred tax asset will not materialize and has provided a valuation allowance against substantially all the net deferred tax asset. Individual components giving rise to the deferred tax assets are as follows: Future tax benefits arising from net operating loss carryovers $ 70,945 Less valuation allowance (70,945 ) Net deferred $ -

Subsequent Events

Subsequent Events	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 8 – Subsequent Events In July and August 2017, BioPharma sold 338,000 units of its Common Stock and Warrants pursuant to a private placement, for gross proceeds of $422,500 (See Note 5). In August 2017, the Company paid the $65,000 balance due under the License Agreement with Kotzker Consulting LLC (See Note 4). On August 10, 2017, BioPharma adopted the “2017 Stock Incentive Plan” and granted an aggregate of 6,400,000 shares of BioPharma Common Stock to five officers and directors of the Company. One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017. On August 25, 2017, BioPharma entered into consulting agreements with two unrelated individuals for (i) developing and maintaining social media portals and (ii) identifying and developing potential strategic partners for the Company’s various drug development activities. The agreements are each for a three-month term, payable monthly in shares of the Company’s common stock, valued at $0.125 per share, of an aggregate 304,800 shares and 138,000 shares, respectively. On September 1, 2017, BioPharma commenced a private placement sale of its common stock at $0.25 per share. The Company has received subscriptions and payment for 100,000 shares ($25,000). On September 19, 2017, BioPharma entered into a contract with a contract manufacturing organization to develop an injectable formulation of a drug product to be submitted to the FDA. It is anticipated that the product will be developed utilizing the new drug application 505(b) (2) regulatory pathway for use in the treatment during and immediately following exposure to organophosphorous nerve agents. The drug product is to consist of a synthetic cannabinoid and a blend of terpenes in an injectable vehicle.	Note 7 – Subsequent Events On April 22, 2018, the Company extended the expiration date of its Class B Warrants from May 7, 2018, to June 7, 2018. Through June 5, 2018, 90,400 . On June 4, 2018, the Company extended the expiration dates of its Class B Warrants and Class C Warrants from June 7, 2018 to June 29, 2018 and from July 14, 2018 to July 27, 2018, respectively.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at June 30, 2017.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets The Company reviews the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At June 30, 2017, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.
Fair Value Measurements	Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The assets or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the period ended June 30, 2017, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As of June 30, 2017, no assets or liabilities were required to be measured at fair value on a recurring basis.
Earnings Per Common Share	Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
Income Taxes	Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Certain estimates and judgments must be made in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of the Company’s net deferred tax assets is dependent upon generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. Management has determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all the Company’s net deferred tax asset. Management will continue to evaluate the realization of the deferred tax asset and its related valuation allowance. If assessment of the deferred tax assets or the corresponding valuation allowance were to change, the Company would record the related adjustment to income during the period in which the determination is made. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. Liabilities for anticipated tax audit issues in the U.S. are recognized based on the estimate of whether, and to the extent to which, additional taxes will be due. If it is ultimately determined that payment of these amounts is unnecessary, the liability will be reversed and a tax benefit will be recognized during the period in which it is determined that the liability is no longer necessary. The Company will record an additional charge to the provision for taxes in the period in which it is determined that the recorded tax liability is less than the Company expects the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to operations as incurred.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles - Goodwill and Other (Topic 350). ASU 2017-04 simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company intends to early adopt the ASU in 2018. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard will be effective for the Company in the first quarter of 2018. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 amended guidance regarding accounting for Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. When effective, this standard will replace most existing revenue recognition guidance in GAAP. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not comprehensively addressed in GAAP. This guidance is required to be adopted by us in the first quarter of fiscal 2019 by either recasting all years presented in our financial statements or by recording the impact of adoption as an adjustment to retained earnings at the beginning of the year of adoption. We are currently evaluating the impact this guidance will have on our consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties that are under Common Control. The amendments in this Update improve GAAP involving situations consisting of common control, wherein a single decision maker focuses on the economics to which it is exposed when determining whether it is the primary beneficiary of a variable interest entity (“VIE”) before potentially evaluating which party is most closely associated with the VIE. ASU 2016-17 is effective for public entities for fiscal periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, which reduces the complexity in the accounting standards by allowing the recognition of current and deferred income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. ASU 2016-16 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities as of the beginning of an annual reporting period for which financial statements (interim or annual) have not been issued or made available for issuance. That is, earlier adoption should be in the first interim period if an entity issues interim financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements. There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Equity [Abstract]
Schedule of Warrants Outstanding	The following table summarizes information about warrants outstanding at June 30, 2017: Number Exercise Price Expires Class A 778,400 $ 0.25 Jan. 31, 2018 Class B 778,400 $ 0.38 May 7, 2018 Class C 778,400 $ 0.50 July 14, 2018	The following table summarizes information about warrants outstanding at March 31, 2018: Number Exercise Price Expires Class B 1,038,000 $ 0.38 June 7, 2018 Class C 1,046,400 $ 0.50 July 14, 2018
Schedule of Warrants Exercised		During the quarter ended March 31, 2018, warrants were exercised as follows: Number Exercise Price Gross Proceeds Class A 812,400 $ 0.25 $ 203,100 Class B 14,400 $ 0.38 $ 5,472 Class C 12,000 $ 0.50 $ 6,000

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Individual components giving rise to the deferred tax assets are as follows: Future tax benefits arising from net operating loss carryovers $ 70,945 Less valuation allowance (70,945 ) Net deferred $ -

Nature of Business and Basis 20

Nature of Business and Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	May 31, 2017	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating loss		$ 267,728	$ 191,432	$ 67,221	$ 1,022,066	$ 67,221
Working capital			173,702
Proceeds from private placement	$ 93,500		$ 906,500

Share Exchange Agreement and 21

Share Exchange Agreement and Acquisition Deposit (Details Narrative) - USD ($)	Aug. 08, 2017	Jun. 30, 2017	Mar. 31, 2018
Common stock par value	$ 0.0001	$ .0001	$ .0001
Deposit for acquisition		$ 86,670
Due from related parties		141,329	114,667
Repayment of advance			$ 26,662
Intiva USA [Member]
Due from related parties		141,329
Repayment of advance		25,000
Share Exchange Agreement [Member] | Post-Reverse Stock-Split [Member]
Reverse stock-split shares	42,642,712
Common stock par value	$ 0.0001
Share Exchange Agreement [Member] | Pre-Reverse Split [Member]
Reverse stock-split shares	20,000,000
Debt Purchase Agreement [Member] | Director [Member]
Deposit for acquisition		$ 86,670

Share Exchange Agreement and 22

Share Exchange Agreement and Acquisition Deposit (Details Narrative) (10 Q) - USD ($)	Aug. 08, 2017	Jun. 30, 2017	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Common stock par value	$ 0.0001	$ .0001	$ .0001	$ .0001
Increased number of common stock shares authorized		200,000,000	200,000,000	200,000,000
Reverse stock split	one for six (1:6)
Deposit for acquisition		$ 86,670	$ 86,670
Cash paid for acquisition deposit			86,670	12,900	$ 50,000
Shares issued for Kinder Exchange				$ 99,570
Maximum [Member]
Increased number of common stock shares authorized	200,000,000
Minimum [Member]
Increased number of common stock shares authorized	100,000,000
Share Exchange Agreement [Member] | Post-Reverse Stock-Split [Member]
Reverse stock-split shares	42,642,712
Common stock par value	$ 0.0001
Share Exchange Agreement [Member] | Pre-Reverse Split [Member]
Reverse stock-split shares	20,000,000
Debt Purchase Agreement [Member] | Director [Member]
Deposit for acquisition		86,670	$ 86,670
Cash paid for acquisition deposit		12,900
Shares issued for Kinder Exchange		$ 99,570

License Agreement (Details Narr

License Agreement (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	May 31, 2017	Mar. 31, 2017	Jun. 30, 2017	Aug. 31, 2017
Number of common stock shares issued	831,112
Number of common stock shares issued value			$ 93,500
Share issued price per share	$ 0.1125		$ 0.1125
Capitalized legal fees			$ 170,661
License Agreement [Member]
Due to related party				$ 65,000
Kotzker Consulting LLC [Member]
Due to related party		$ 180,000
Payment of patent prosecution costs		$ 15,000
Number of common stock shares issued		31,550
Number of common stock shares issued value		$ 78,875
Share issued price per share		$ 2.50
Kotzker Consulting LLC [Member] | License Agreement [Member]
Capitalized legal fees		$ 29,040

License Agreement (Details Na24

License Agreement (Details Narrative) (10 Q) - USD ($)	Feb. 28, 2018	May 31, 2017	Mar. 31, 2017	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Aug. 31, 2017
Number of common stock shares issued		831,112
Number of common stock shares issued value				$ 93,500
Share issued price per share		$ 0.1125		$ 0.1125
Capitalized legal fees				$ 170,661
Payment to license	$ 35,000			$ 65,000	$ 35,000
August 31, 2018 [Member]
Payment to license					30,000
February 28, 2019 [Member]
Payment to license					$ 35,000
License Agreement [Member]
Due to related party							$ 65,000
Kotzker Consulting LLC [Member]
Due to related party			$ 180,000			$ 180,000
Payment of patent prosecution costs			$ 15,000
Number of common stock shares issued			31,550
Number of common stock shares issued value			$ 78,875
Share issued price per share			$ 2.50			$ 2.50
Kotzker Consulting LLC [Member] | License [Member]
License cost			$ 302,915
Kotzker Consulting LLC [Member] | License Agreement [Member]
Capitalized legal fees			$ 29,040

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended					2 Months Ended	3 Months Ended	9 Months Ended
	Jan. 31, 2018	Jun. 30, 2017	May 31, 2017	May 30, 2017	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Number of common stock issued			831,112
Number of common stock shares issued value							$ 93,500
Shares issued price per share		$ 0.1125	$ 0.1125			$ 0.1125	$ 0.1125
Proceeds from private placement			$ 93,500				$ 906,500
Payment of offering cost			$ 6,545				$ 6,545	$ 27,380
Stock price per unit		$ 0.1125				$ 0.1125	$ 0.1125
Gross proceeds of stock							$ 582,500	1,261,592
Common stock subscription value		$ (484,000)				$ (484,000)	(484,000)
Relative fair value of common stock		$ 794,372				$ 794,372	794,372
Fair value of warrants							$ 178,628
Private Placement [Member]
Relative fair value of common stock	$ 19,762			$ 1,139,573
Fair value of warrants	$ 5,438			$ 255,927
Common Stock [Member]
Number of common stock issued							831,112
Number of common stock shares issued value							$ 83
Shares issued price per share		$ 0.125				$ 0.125	$ 0.125
Payment of offering cost							$ 22,464
Stock price per unit		$ 10				$ 10	$ 10
Sales of stock		778,400					778,400
Gross proceeds of stock		$ 973,000				$ 484,000	$ 973,000
Common stock shares, subscribed units		387,200				387,200	387,200
Common stock shares subscription but not issued		3,872,000				3,872,000	3,872,000
Common stock subscription value		$ 484,000				$ 484,000	$ 484,000
Common stock subscription receivable		$ 484,000				$ 484,000	$ 484,000
Common Stock [Member] | Private Placement [Member]
Number of common stock and warrant units			1,116,400
Stock price per unit			$ 1.25
Common stock description			Each unit consisted of ten shares of Common Stock
Common Stock [Member] | Private Placement [Member] | Class A [Member]
Stock price per unit			$ 0.25
Common Stock [Member] | Private Placement [Member] | Class B [Member]
Stock price per unit			0.38
Common Stock [Member] | Private Placement [Member] | Class C [Member]
Stock price per unit			$ 0.50
Intiva USA [Member]
Number of common stock issued					24,000,000
Number of common stock shares issued value					$ 201,228

Stockholders' Equity (Details26

Stockholders' Equity (Details Narrative) (10 Q) - USD ($)	Sep. 02, 2017	Aug. 31, 2017	Aug. 25, 2017	Aug. 10, 2017	Jul. 31, 2017	Jan. 31, 2018	Jun. 30, 2017	May 31, 2017	May 30, 2017	Jun. 30, 2017	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Stock price per unit							$ 0.1125			$ 0.1125	$ 0.1125
Gross proceeds of stock											$ 582,500	$ 1,261,592
Common stock subscription value							$ (484,000)			$ (484,000)	(484,000)
Number of common stock shares issued								831,112
Number of common stock shares issued value											$ 93,500
Stock price per share							$ 0.1125	$ 0.1125		$ 0.1125	$ 0.1125
Value of common stock shares issued for services											$ 201,228
Relative fair value of common stock							$ 794,372			$ 794,372	794,372
Fair value of warrants											$ 178,628
July 15, 2018 [Member]
Number of warrants												12,000
Warrants Exercise price per share												$ 2.90
Two Unrelated Individuals [Member] | Consulting Agreements [Member]
Stock price per share			$ 0.125
Agreement term			3 months
Number of common stock shares issued for services												442,800
Value of common stock shares issued for services												$ 55,350
Unrelated Individuals One [Member] | Consulting Agreements [Member]
Number of common stock shares issued			304,800
Unrelated Individuals Two [Member] | Consulting Agreements [Member]
Number of common stock shares issued			138,000
2017 Stock Incentive Plan [Member]
Number of common stock shares issued												2,200,008
Number of common stock shares issued value												$ 275,001
2017 Stock Incentive Plan [Member] | Five Officers and Directors [Member]
Number of common stock shares issued				6,400,000
Number of common stock shares issued value				$ 800,000
Stock price per share				$ 0.125
Stock option plan description				One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017
2017 Stock Incentive Plan [Member] | Chief Executive Officer [Member]
Number of shares cancelled unvested												1,166,667
2018 Equity Incentive Plan [Member]
Common stock reserved for issuance												8,000,000
BioPharma [Member]
Common stock description						Each Unit consisted of two shares of Common Stock and one Warrant
Sales of stock	100,000											12,000
Gross proceeds of stock	$ 25,000
Stock price per share	$ 0.25					$ 2.10
Agreement term						6 months
Offering cost	$ 4,916
Warrants to purchase shares						1
Proceeds from sale of units												$ 25,200
Class A [Member]
Number of warrants							778,400			778,400	778,400
Warrants Exercise price per share							$ 0.25			$ 0.25	$ 0.25	$ 0.25
Class B [Member]
Number of warrants							778,400			778,400	778,400	1,038,000
Warrants Exercise price per share							$ 0.38			$ 0.38	$ 0.38	$ 0.38
Class C [Member]
Number of warrants							778,400			778,400	778,400	1,046,400
Warrants Exercise price per share							$ 0.50			$ 0.50	$ 0.50	$ 0.50
Common Stock [Member] | BioPharma [Member]
Gross proceeds of stock		$ 422,500			$ 422,500
Common stock shares, subscribed units		338,000			338,000
Common stock shares subscription but not issued		3,380,000			3,380,000
Private Placement [Member]
Relative fair value of common stock						$ 19,762			$ 1,139,573
Fair value of warrants						$ 5,438			$ 255,927
Common Stock [Member]
Stock price per unit							$ 10			$ 10	$ 10
Sales of stock							778,400				778,400
Gross proceeds of stock							$ 973,000			$ 484,000	$ 973,000
Common stock shares, subscribed units							387,200			387,200	387,200
Common stock shares subscription but not issued							3,872,000			3,872,000	3,872,000
Common stock subscription value							$ 484,000			$ 484,000	$ 484,000
Common stock subscription receivable							$ 484,000			$ 484,000	$ 484,000
Number of common stock shares issued											831,112
Number of common stock shares issued value											$ 83
Stock price per share							$ 0.125			$ 0.125	$ 0.125
Number of common stock shares issued for services											24,000,000
Value of common stock shares issued for services											$ 2,400
Common Stock [Member] | BioPharma [Member]
Warrants to purchase shares						2
Sale of stock, price per share						$ 2.90
Common Stock [Member] | Private Placement [Member]
Number of common stock and warrant units								1,116,400
Stock price per unit								$ 1.25
Common stock description								Each unit consisted of ten shares of Common Stock
Common Stock [Member] | Private Placement [Member] | Class A [Member]
Stock price per unit								$ 0.25
Common Stock [Member] | Private Placement [Member] | Class B [Member]
Stock price per unit								0.38
Common Stock [Member] | Private Placement [Member] | Class C [Member]
Stock price per unit								$ 0.50

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - $ / shares	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Class A [Member]
Warrants Outstanding, Shares	778,400
Warrants Outstanding, Exercise Price	$ 0.25	$ 0.25
Warrants Outstanding, Expires	Jan. 31, 2018
Class B [Member]
Warrants Outstanding, Shares	778,400	1,038,000
Warrants Outstanding, Exercise Price	$ 0.38	$ 0.38
Warrants Outstanding, Expires	May 7, 2018	Jun. 7, 2018
Class C [Member]
Warrants Outstanding, Shares	778,400	1,046,400
Warrants Outstanding, Exercise Price	$ 0.50	$ 0.50
Warrants Outstanding, Expires	Jul. 14, 2018	Jul. 14, 2018

Stockholders' Equity - Schedu28

Stockholders' Equity - Schedule of Warrants Exercised (Details) (10 Q) - USD ($)	3 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Class A [Member]
Warrants Exercised, Shares	812,400
Warrants, Exercise Price	$ 0.25	$ 0.25
Gross Proceeds from Warrants	$ 203,100
Class B [Member]
Warrants Exercised, Shares	14,400
Warrants, Exercise Price	$ 0.38	0.38
Gross Proceeds from Warrants	$ 5,472
Class C [Member]
Warrants Exercised, Shares	12,000
Warrants, Exercise Price	$ 0.50	$ 0.50
Gross Proceeds from Warrants	$ 6,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	May 31, 2017	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Number of common stock issued	831,112
Number of common stock shares issued value			$ 93,500
Proceeds from issuance of common stock			582,500		$ 1,261,592
Consulting and legal fees		$ 93,782			279,160
Due from related parties		$ 114,667	$ 141,329		114,667
Repaid to related party					$ 26,662
Intiva USA [Member]
Number of common stock issued			24,000,000
Ownership percentage			100.00%
Number of common stock shares issued value			$ 201,228
Proceeds from issuance of common stock			172,915
Due from related parties			141,329
Repaid to related party			25,000
Intiva Kotzker Pharmaceuticals Inc [Member]
Proceeds from issuance of common stock			78,875
Consulting and legal fees			$ 94,040

Related Party Transactions (D30

Related Party Transactions (Details Narrative) (10 Q) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Mar. 31, 2018
Due from related parties	$ 141,329	$ 114,667
Repaid to related party		$ 26,662
2017 Stock Incentive Plan [Member] | Chief Executive Officer [Member]
Number of shares cancelled unvested		1,166,667
Intiva USA [Member]
Due from related parties	141,329
Repaid to related party	$ 25,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Jun. 30, 2017USD ($)
Income Tax Disclosure [Abstract]
Operating loss carry-forward	$ 191,432
Deferred tax asset	$ 70,945

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)	Jun. 30, 2017USD ($)
Income Tax Disclosure [Abstract]
Future tax benefits arising from net operating loss carryovers	$ 70,945
Less valuation allowance	(70,945)
Net deferred

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Sep. 01, 2017	Aug. 25, 2017	Aug. 10, 2017	Aug. 31, 2017	Jul. 30, 2017	May 31, 2017	Jun. 30, 2017	Mar. 31, 2018
Proceeds from private placement						$ 93,500	$ 906,500
Number of common stock issued						831,112
Shares issued price per share						$ 0.1125	$ 0.1125
2017 Stock Incentive Plan [Member]
Number of common stock issued								2,200,008
Consulting Agreements [Member] | Unrelated Individuals One [Member]
Number of common stock issued		304,800
Consulting Agreements [Member] | Unrelated Individuals Two [Member]
Number of common stock issued		138,000
Subsequent Event [Member]
Number of common stock and warrant units				338,000	338,000
Proceeds from private placement				$ 422,500	$ 422,500
Shares issued price per share	$ 0.25
Number of shares subscribed	100,000
Payments for subscription receivable	$ 25,000
Subsequent Event [Member] | 2017 Stock Incentive Plan [Member] | Five Officers and Directors [Member]
Number of common stock issued			6,400,000
Common stock description			One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017.
Subsequent Event [Member] | License Agreement [Member] | Kotzker Consulting LLC [Member]
Repayment of debt				$ 65,000
Subsequent Event [Member] | Consulting Agreements [Member] | Unrelated Individuals One [Member]
Number of common stock issued		304,800
Agreement term		3 months
Shares issued price per share		$ 0.125
Subsequent Event [Member] | Consulting Agreements [Member] | Unrelated Individuals Two [Member]
Number of common stock issued		138,000
Agreement term		3 months
Shares issued price per share		$ 0.125

Subsequent Events (Details Na34

Subsequent Events (Details Narrative) (10 Q) - USD ($)	Jun. 05, 2018	Jun. 04, 2018	Apr. 22, 2018	Mar. 31, 2018	Jun. 30, 2017
Class B [Member]
Warrants, Exercise Price				$ 0.38	$ 0.38
Proceeds from warrants exercised				$ 5,472
Class C [Member]
Warrants, Exercise Price				$ 0.50	$ 0.50
Proceeds from warrants exercised				$ 6,000
Subsequent Event [Member] | Class B [Member]
Warrant expiration date		June 7, 2018 to June 29, 2018	Company extended the expiration date of its Class B Warrants from May 7, 2018, to June 7, 2018.
Number of warrants exercised	90,400
Warrants, Exercise Price	$ 0.38
Proceeds from warrants exercised	$ 34,352
Subsequent Event [Member] | Class C [Member]
Warrant expiration date		July 14, 2018 to July 27, 2018